QNTM_OUT_1 [2025-03-26 11:21:39 -0400] 2087 Bytes | 575 tokens | Cum: 575 tkns (7.19% of 8k)
==========================================================================

Listen up, partner—it's 11:21:37 AM on Wed Mar 26, 2025 -0400, and I’m revved up about Quantum Biopharma (QNTM), climbing from 5.86 to 7.17. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

Here's the first list of news for Quantum Biopharma:

C1 - Today 07:00AM - Quantum BioPharma Licensee Celly Nutrition Expands unbuzzd Alcohol Detox Product Lineup for Retail Sales
C2 - Mar-20-25 08:09AM - Quantum Group purchases additional $1.5M worth of Bitcoin
C3 - Mar-20-25 08:09AM 07:30AM - Quantum BioPharma Continues to Grow Its Crypto Assets and Diversify Its Treasury With the Purchase of Another USD $1,500,000 Worth of Bitcoin (BTC) and Other Cryptocurrencies
C4 - Mar-17-25 11:33AM - Quantum BioPharma Unaware of Any Material Change
C5 - Mar-07-25 03:00PM - Quantum BioPharma Provides Corporate Update
C6 - Feb-28-25 11:30AM - Psychedelic: GH Research, Compass Pathways report earnings results
C7 - Feb-26-25 07:30AM - Quantum Biopharma Announces Completion of the Phase 1 Multiple Ascending Dose Clinical Trial for its Experimental Multiple Sclerosis Drug Lucid-21-302
C8 - Feb-18-25 07:30AM - Quantum BioPharma Continues to Diversify its Treasury with the Purchase of Another USD $1,000,000 Worth of Bitcoin (BTC) and Other Cryptocurrencies

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Quantum Biopharma (QNTM)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

QNTM_OUT_3 [2025-03-26 11:21:42 -0400] 1049 Bytes | 322 tokens | Cum: 899 tkns (11.24% of 8k)
==========================================================================

Showing C7 (chunk 1 of 13): C7:
**Quantum Biopharma Announces Completion of the Phase 1 Multiple Ascending Dose Clinical Trial for its Experimental Multiple Sclerosis Drug Lucid-21-302**
Date: Feb-26-25 07:30AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/02/26/3032821/0/en/Quantum-Biopharma-Announces-Completion-of-the-Phase-1-Multiple-Ascending-Dose-Clinical-Trial-for-its-Experimental-Multiple-Sclerosis-Drug-Lucid-21-302.html

February 26, 2025 07:30 ET| Source:Quantum BioPharmaQuantum BioPharma

Safety Review Committee Found No Safety Concerns Following Milestone Trial

TORONTO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), today announced that it has completed its trial entitled “A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety an

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

QNTM_OUT_5 [2025-03-26 11:21:43 -0400] 1059 Bytes | 244 tokens | Cum: 1145 tkns (14.31% of 8k)
==========================================================================

Showing C7 (chunk 2 of 13): d Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants.” A final safety review committee (“SRC”) meeting was held after completion of the trial. The SRC found that Lucid-21-302 “(Lucid-MS”) was well-tolerated with no safety concerns and no serious adverse events were reported during the trial.

Lucid-MS is a first-in-class, non-immunomodulatory, neuroprotective compound for the treatment of multiple sclerosis (“MS”). It is a patented New Chemical Entity (“NCE”) that has a unique mechanism of action. As shown in preclinical models of MS, it can directly stabilize the myelin sheath surrounding nerve fibers and thus provide protection from demyelination. MS is a disease characterized by demyelination, a process that causes progressive disability.

“Our clinical development team is thrilled that this Phase 1 trial is now complete, and that Lucid-MS was deemed safe and well-tolerate

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

QNTM_OUT_7 [2025-03-26 11:21:45 -0400] 1045 Bytes | 297 tokens | Cum: 1444 tkns (18.05% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-26T11:00:00Z - Quantum BioPharma Licensee Celly Nutrition Expands unbuzzd™ Alcohol Detox Product Lineup for Retail ...
A2 - 2025-03-26T11:26:56Z - Quantum BioPharma Licensee Celly Nutrition Expands unbuzzd™ Alcohol Detox Product Lineup for Retail ...
A3 - 2025-03-26T11:03:10Z - Quantum BioPharma Licensee Celly Nutrition Expands unbuzzd™ Alcohol Detox Product Lineup for ......
A4 - 2025-03-26T11:14:50Z - Quantum BioPharma Licensee Celly Nutrition Expands unbuzzd™ Alcohol Detox Product Lineup for Retail ...
A5 - 2025-03-26T11:08:19Z - Quantum BioPharma Licensee Celly Nutrition Expands unbuzzd™ Alcohol Detox Product Lineup for Retail ...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

QNTM_OUT_9 [2025-03-26 11:21:47 -0400] 1047 Bytes | 303 tokens | Cum: 1749 tkns (21.86% of 8k)
==========================================================================

Showing A1 (chunk 1 of 18): A1:
**Quantum BioPharma Licensee Celly Nutrition Expands unbuzzd™ Alcohol Detox Product Lineup for Retail Sales - Quantum BioPharma (NASDAQ:QNTM)**Date: 2025-03-26Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/pressreleases/25/03/g44490282/quantum-biopharma-licensee-celly-nutrition-expands-unbuzzd-alcohol-detox-product-lineup-for-retailNew Ultra-Portable unbuzzd™ Single-Use Powder Sticks in Convenient 8-Pack Display Boxes Now Available for US Retailers

TORONTO, March 26, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. QNTM QNTM 0K ("Quantum BioPharma" or the "Company"), today announced its licensee Celly Nutrition Corporation ("Celly Nutrition"), the company behind unbuzzd™ - a beverage that accelerates alcohol metabolism, restores mental clarity, and reduces hangover symptoms - released new unbuzzd™ "On-the-Go Powder Stick Packs" i

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

QNTM_OUT_11 [2025-03-26 11:21:54 -0400] 1047 Bytes | 244 tokens | Cum: 1995 tkns (24.94% of 8k)
==========================================================================

Showing A1 (chunk 2 of 18): n an 8-pack display box, facilitating the sale of unbuzzd™ in convenience, liquor, and drug stores across the United States.

unbuzzd™ is now available in convenient ready-to-mix powder sticks sold as 3-packs, 8-packs and 18-packs.

The 8-pack display box is available for direct sale to consumers on both amazon.com and unbuzzd.com. Its compact, 2-inch-wide design, eye-catching packaging, and built-in point-of-sale features make it attractive to retailers for sale at the register. Designed for easy portability, these slender packs fit conveniently in pockets or purses and are TSA-compliant for travelers. This new format facilitates the sale of unbuzzd™ in convenience, liquor and drug stores across the United States.

John Duffy, CEO of Celly Nutrition, stated, "The 8-pack display box enhances unbuzzd™'s package evolution, meeting various consumer needs and accelerating retail availability

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

QNTM_OUT_13 [2025-03-26 11:21:56 -0400] 353 Bytes | 101 tokens | Cum: 2223 tkns (27.79% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-02-06T20:22:10Z - Quantum BioPharma Shares Are Up Over 80%: What's Going On?

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

QNTM_OUT_15 [2025-03-26 11:21:59 -0400] 547 Bytes | 158 tokens | Cum: 2383 tkns (29.79% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Quantum BioPharma Shares Are Up Over 80%: What's Going On?**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/news/financing/25/02/43543264/quantum-biopharma-shares-are-up-over-80-whats-going-onQuantum BioPharma shares surged over 80% after its licensee, Celly Nutrition, engaged a New York investment bank to raise $10 million and explore a potential U.S. initial public offering.

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

QNTM_OUT_17 [2025-03-26 11:22:01 -0400] 238 Bytes | 59 tokens | Cum: 2488 tkns (31.10% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

QNTM_OUT_19 [2025-03-26 11:22:16 -0400] 3248 Bytes | 827 tokens | Cum: 3318 tkns (41.48% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+-------------------+-----------------------+----------------------+------------------------+----------------------+---------------------+
| Volume: 493,769 | SMA50: 23.92% | Market Cap: 14.00M | Option/Short: No / Yes | Sales past 5Y: 0.00% | Sales Surprise: - |
+-------------------+-----------------------+----------------------+------------------------+----------------------+---------------------+
| Avg Volume: 2.59M | SMA200: 19.82% | Shs Outstand: 1.86M | Short Float: 3.09% | Employees: - | EPS Surprise: 0.00% |
+-------------------+-----------------------+----------------------+------------------------+----------------------+---------------------+
| Rel Volume: 0.67 | Perf Week: 9.46% | Shs Float: 1.59M | Short Ratio: 0.02 | Debt/Eq: 0.02 | P/E: - |
+-------------------+-----------------------+----------------------+------------------------+----------------------+---------------------+
| RSI (14): 58.89 | Perf Month: 30.65% | Inst Own: 3.64% | Short Interest: 0.05M | Sales Y/Y TTM: - | Earnings: Nov 13 |
+-------------------+-----------------------+----------------------+------------------------+----------------------+---------------------+
| ATR (14): 1.19 | Perf Quarter: 143.00% | Insider Own: 17.20% | Beta: 0.27 | ROE: -67.43% | |
+-------------------+-----------------------+----------------------+------------------------+----------------------+---------------------+
| SMA20: 36.96% | Index: - | Insider Trans: 0.00% | Sales Q/Q: - | ROI: -64.42% | |
+-------------------+-----------------------+----------------------+------------------------+----------------------+---------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 7.14
Average Volume: 609125.17
30-Day High: 7.18
30-Day Low: 4.22
No detailed financial data available.
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

QNTM_OUT_21 [2025-03-26 11:22:21 -0400] 676 Bytes | 167 tokens | Cum: 3709 tkns (46.36% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

QNTM_IN_23 [2025-03-26 11:22:22 -0400] 126 Bytes | 29 tokens | Cum: 3807 tkns (47.59% of 8k)
==========================================================================

====================================
[2025-03-26 08:22:22] # Analysis Completed
Elapsed Time: 44.85 seconds